| Assessment Status | Rapid review complete |
| HTA ID | 22052 |
| Drug | Eptinezumab |
| Brand | Vyepti® |
| Indication | For the prophylaxis of migraine in adults who have at least four migraine days per month |
| Assessment Process | |
| Rapid review commissioned | 20/07/2022 |
| Rapid review completed | 16/09/2022 |
| Rapid review outcome | A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of eptinezumab (Vyepti®) compared with the current standard of care, on the basis of the proposed price relative to currently available therapies* |
